Skip to main content
Erschienen in: Indian Journal of Hematology and Blood Transfusion 4/2017

21.03.2017 | Original Article

Buccal Mucosa Exfoliative Cell Prussian Blue Stain Co-Relates with Iron Overload in β-Thalassemia Major Patients

verfasst von: Pooja K. Gajaria, Ujwala M. Maheshwari, D. B. Borkar, Reeta Dhar, Varsha Pancholi

Erschienen in: Indian Journal of Hematology and Blood Transfusion | Ausgabe 4/2017

Einloggen, um Zugang zu erhalten

Abstract

Thalassemics require regular blood transfusion therapy leading to iron overload in the body tissues, which is a major cause of morbidity and mortality in these patients. We hereby attempted to measure this iron overload by means of exfoliative cytology, a non-invasive and inexpensive technique. The aims and objectives of our study were: 1. To detect iron overload by oral exfoliative cytology using Perl’s Prussian blue stain in β-thalassemia major patients. 2. To correlate staining positivity with serum ferritin levels. Smears were obtained from buccal mucosa of 50 β-thalassemia major patients (who had taken more than 12 transfusions) and 25 healthy subjects of the same age group as controls. Smears were stained with Perl’s Prussian blue. Blood samples were taken from the study group for estimation of serum ferritin levels. Grading criteria were defined for assessing the Prussian blue positivity. Perl’s positivity was observed in 49 out of 50 of thalassemic patients (98%). 1 patient had Grade 0, 7 patients had Grade I, 5 had Grade II, 12 had Grade III, 14 had Grade IV while 11 patients had Grade V positivity. Spearman Rank’s Correlation Co-efficient was 0.38, signifying a weak positive correlation between positivity of buccal smears for Perl’s Prussian blue staining and respective serum ferritin levels. Perl’s Prussian blue staining of exfoliated cells from buccal mucosa can be used to assess iron overload in β-thalassemia major patients, as a screening as well as diagnostic tool. With the grading system we can give a semi-quantitative assessment of the same.
Literatur
1.
Zurück zum Zitat Greer JP, Arber DA, Glader B, List AF, Means RT, Frixos P, Rodgers GM (2014) Wintrobe’s Clinical Hematology, 13th edn. Wolters Kluwer Lippincott Williams and Wilkins Health Greer JP, Arber DA, Glader B, List AF, Means RT, Frixos P, Rodgers GM (2014) Wintrobe’s Clinical Hematology, 13th edn. Wolters Kluwer Lippincott Williams and Wilkins Health
2.
Zurück zum Zitat Brittenham G, Cohen A, McLaren C, Martin M, Griffith P, Nienhuis A et al (1993) Hepatic iron stores and plasma ferritin concentration in patients with sickle cell anemia and thalassemia major. Am J Hematol 42(1):81–85CrossRefPubMed Brittenham G, Cohen A, McLaren C, Martin M, Griffith P, Nienhuis A et al (1993) Hepatic iron stores and plasma ferritin concentration in patients with sickle cell anemia and thalassemia major. Am J Hematol 42(1):81–85CrossRefPubMed
3.
Zurück zum Zitat Ghugre N, Enriquez C, Gonzalez I, Nelson M, Coates T, Wood J (2006) MRI detects myocardial iron in the human heart. Magn Reson Med 56(3):681–686CrossRefPubMedPubMedCentral Ghugre N, Enriquez C, Gonzalez I, Nelson M, Coates T, Wood J (2006) MRI detects myocardial iron in the human heart. Magn Reson Med 56(3):681–686CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Gururaj N, Sundharam S (2003) Demonstration of iron in the exfoliated cells of the oral mucosa. J Oral Maxillofac Pathol 1:37–39 Gururaj N, Sundharam S (2003) Demonstration of iron in the exfoliated cells of the oral mucosa. J Oral Maxillofac Pathol 1:37–39
5.
Zurück zum Zitat Nandprasad S, Sharada P, Vidya M, Karkera B, Hemanth M, Prakash N (2009) Oral exfoliative cytology in beta thalassemia patients undergoing repeated blood transfusions. Internet J Pathol 10:7 Nandprasad S, Sharada P, Vidya M, Karkera B, Hemanth M, Prakash N (2009) Oral exfoliative cytology in beta thalassemia patients undergoing repeated blood transfusions. Internet J Pathol 10:7
6.
Zurück zum Zitat Bhat Atul A, Parwani RK, Wanjari SP (2013) Demonstration of Iron in exfoliated buccal cells of β thalassemia major Patients. J Cytol 30(3):169–173CrossRefPubMedPubMedCentral Bhat Atul A, Parwani RK, Wanjari SP (2013) Demonstration of Iron in exfoliated buccal cells of β thalassemia major Patients. J Cytol 30(3):169–173CrossRefPubMedPubMedCentral
7.
Zurück zum Zitat Chittamsetty H, Munishekar Syed, Ahmed Afroz, Palla Churu Suri Sridevi et al (2013) A Non- invasive Technique which demonstrate iron in the buccal mucosa of sickle cell anaemia and thalessemia patients who undergo repeated blood transfusion. J Clin Diag Res 7(6):1219–1222 Chittamsetty H, Munishekar Syed, Ahmed Afroz, Palla Churu Suri Sridevi et al (2013) A Non- invasive Technique which demonstrate iron in the buccal mucosa of sickle cell anaemia and thalessemia patients who undergo repeated blood transfusion. J Clin Diag Res 7(6):1219–1222
8.
Zurück zum Zitat Gupta S, Trichal VK, Malik R, Nigam RK, Choudhary R, Shrivastava A (2014) Perls’ prussian blue positivity in exfoliated buccal cells of β thalessemia major patients and its correlation with serum ferritin. J Evol Med Dental Sci 3(19):5135–5140CrossRef Gupta S, Trichal VK, Malik R, Nigam RK, Choudhary R, Shrivastava A (2014) Perls’ prussian blue positivity in exfoliated buccal cells of β thalessemia major patients and its correlation with serum ferritin. J Evol Med Dental Sci 3(19):5135–5140CrossRef
Metadaten
Titel
Buccal Mucosa Exfoliative Cell Prussian Blue Stain Co-Relates with Iron Overload in β-Thalassemia Major Patients
verfasst von
Pooja K. Gajaria
Ujwala M. Maheshwari
D. B. Borkar
Reeta Dhar
Varsha Pancholi
Publikationsdatum
21.03.2017
Verlag
Springer India
Erschienen in
Indian Journal of Hematology and Blood Transfusion / Ausgabe 4/2017
Print ISSN: 0971-4502
Elektronische ISSN: 0974-0449
DOI
https://doi.org/10.1007/s12288-017-0801-4

Weitere Artikel der Ausgabe 4/2017

Indian Journal of Hematology and Blood Transfusion 4/2017 Zur Ausgabe

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.